# Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Study · id `cardio:ct-nct07939516` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07939516](<https://clinicaltrials.gov/study/NCT07939516>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07939516

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3120 participants.

## Technical summary

Registry record NCT07939516. Randomized; no masking; primary purpose treatment. Start 2026-11-15 (anticipated); primary completion 2029-11-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3120 participants (planned count; ClinicalTrials.gov record NCT07939516, source copy `cardio:ctgov-nct07939516-2026-11-16`, retrieved 2026-11-18)
- Planned start: 2026-11-15 (anticipated) (ClinicalTrials.gov record NCT07939516, source copy `cardio:ctgov-nct07939516-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2029-11-15 (anticipated) (ClinicalTrials.gov record NCT07939516, source copy `cardio:ctgov-nct07939516-2026-11-16`, retrieved 2026-11-18)
- Completion: 2030-03-01 (anticipated) (ClinicalTrials.gov record NCT07939516, source copy `cardio:ctgov-nct07939516-2026-11-16`, retrieved 2026-11-18)
- Countries: Netherlands (ClinicalTrials.gov record NCT07939516, source copy `cardio:ctgov-nct07939516-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07939516-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome
- Acronym: IGNITION
- Condition: Acute Coronary Syndromes (ACS)
- Condition: Unstable Angina Pectoris
- Condition: Myocardial Infarction (MI)
- Condition: STEMI
- Condition: NSTEMI
- Intervention (Drug): Genotype guided P2Y12 therapy
- Intervention (Drug): Standard therapy group
- Lead sponsor: Medisch Spectrum Twente
- Lead sponsor class: OTHER
- Collaborator: Ziekenhuisgroep Twente
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)

## Provenance

Content hash: db85ec7ec0dd502682f668cd135ec291b60fe5d97c628cd51932ccd4e3ecb52a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
